AZN: AstraZeneca PLC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AZN: AstraZeneca PLC

AZN 82.44

-0.2%

2:17 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Eugene E. Dorsey	5/21/2006 9:07:22 AM
	Read Replies (1) of 35

Analyst Opinions MSN Money Opinion: moneycentral.msn.com moneycentral.msn.com Five Analyst opinions for the next 52 wks. High Target: $56.00 Low Target: $23.00 Median Target: $30.00 finance.yahoo.com Cramer's take on AVNR: Avanir's Promising Prospect Avanir Pharmaceuticals (AVNR:Nasdaq - commentary - research - Cramer's Take) just listed on the Nasdaq (it used to trade on the Amex), and, Cramer said, it's time to buy the stock because the Food and Drug Administration has given some of its formulations priority status. The only thing better than a company having pull with the government is a company that has products so good that it doesn't need pull with the government, he said. One of these treatments is Neurodex, which treats pseudobulbar affect (PBA). This condition, which often afflicts people with Lou Gehrig's disease and multiple sclerosis, causes uncontrollable bouts of laughter or tears. The FDA has given Neurodex fast track status, and Cramer said that it should be able to do $150 million in sales if it is approved. biz.yahoo.com Better still, he said that the treatment could also get "orphan drug status," giving it a seven-year monopoly in addition to patent protection. The company is working with Novartis (NVS:NYSE ADR - commentary - research - Cramer's Take) on deals that could earn Avanir $200 million in milestone payments, and is also involved in deals with AstraZeneca (AZN:NYSE ADR - commentary - research - Cramer's Take). thestreet.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next